Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
REGULATORY
Xarelto, Equa Face Generic Debuts in Japan: December Listing
Nine APIs will see the entry of their first generic versions in the biannual generic listing to take place on December 6, including Bayer Yakuhin’s Xarelto (rivaroxaban) and Novartis Pharma/Sumitomo Pharma’s Equa (vildagliptin), the official gazette revealed. Xarelto raked in…
To read the full story
Related Article
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
REGULATORY
- Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
- Lawmakers Urge Chuikyo to Respect Public-Private Council Views
September 11, 2025
- MHLW Panel Urges Tighter Scrutiny of GLP-1 “Weight Loss” Ads
September 11, 2025
- JPMA Pushes for Mandatory Collection of Medical Data, JMA Fires Back
September 11, 2025
- Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…